Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203502 · ClinicalTrials.gov registry record · Phase 2
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00203502 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 40 participants.
The verdict
NCT00203502, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve weeks in combination with chemotherapy then it ill be held during the administration of doxorubicin. Twenty-eight to fifty-six days after undergoing surgery, all patients will receive nine three-weekly infusions of bevacizumab.
Interventions
- DRUG Cyclophosphamide
- DRUG Bevacizumab
- DRUG Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-09 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203502
The ClinicalTrials.gov registry entry for NCT00203502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00203502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203502 about?
NCT00203502 is a clinical study titled "Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer". The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer. Bevacizumab will be given for twelve weeks in combination with chemothe...
What is the current status of trial NCT00203502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-09. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00203502?
The interventions under investigation include: Cyclophosphamide (DRUG), Bevacizumab (DRUG), Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00203502?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.